Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
Eur J Vasc Endovasc Surg ; 67(5): 811-817, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38311050

RESUMO

OBJECTIVE: Superficial venous incompetence (SVI) is a common disease that causes significant quality of life (QoL) impairment. There is a need for more health economic evaluations of SVI treatment. The aim of this study was to perform a cost effectiveness analysis in patients with great saphenous vein (GSV) incompetence comparing radiofrequency ablation (RFA), high ligation and stripping (HL/S), and no treatment or conservative treatment with one year follow up. METHODS: Randomised controlled trial economic analysis from an ongoing trial; 143 patients (156 limbs) with GSV incompetence (CEAP clinical class 2 - 6) were included. Treatment was performed with RFA or HL/S. Follow up was performed up to one year using duplex ultrasound, revised venous clinical severity score (r-VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and EuroQol-5D-3L (EQ-5D-3L). RESULTS: Seventy-eight limbs were treated with RFA and HL/S respectively. No treatment or conservative treatment was assumed to have zero in treatment cost and no treatment benefit. In the RFA group, one limb had reflux in the GSV after one month and three limbs after one year. In HL/S, two limbs had remaining reflux in the treated area at one month and one year. Both disease severity (r-VCSS, p = .004) and QoL (AVVQ, p = .021 and EQ-5D-3L, p = .028) were significantly improved over time. The QALY gain was 0.21 for RFA and 0.17 for HL/S. The cost per patient was calculated as €1 292 for RFA and €2 303 for HL/S. The cost per QALY (compared with no treatment or conservative treatment) was €6 155 for RFA and €13 549 for HL/S. With added cost for days absent from work the cost per QALY was €7 358 for RFA and €24 197 for HL/S. The cost per QALY for both methods was well below the threshold suggested by Swedish National Board of Health. CONCLUSION: RFA is more cost effective than HL/S and no treatment or conservative treatment at one year follow up.


Assuntos
Análise Custo-Benefício , Qualidade de Vida , Ablação por Radiofrequência , Veia Safena , Insuficiência Venosa , Humanos , Ligadura/economia , Veia Safena/cirurgia , Veia Safena/diagnóstico por imagem , Insuficiência Venosa/cirurgia , Insuficiência Venosa/economia , Insuficiência Venosa/diagnóstico por imagem , Feminino , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Ablação por Radiofrequência/economia , Ablação por Radiofrequência/efeitos adversos , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Tempo , Procedimentos Cirúrgicos Vasculares/economia , Procedimentos Cirúrgicos Vasculares/efeitos adversos , Procedimentos Cirúrgicos Vasculares/métodos , Idoso , Ablação por Cateter/economia , Ablação por Cateter/efeitos adversos , Ablação por Cateter/métodos , Adulto , Custos de Cuidados de Saúde , Varizes/cirurgia , Varizes/economia , Varizes/diagnóstico por imagem , Análise de Custo-Efetividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA